Suspension of the de minimis administrative exemption for imports $800 or less
A new U.S. Customs and Border Protection rule suspending the “de minimis” duty exemption for imports under $800 is set to expose all low‑value mail shipments to tariffs, bonds, and full customs paperwork. Commenters warn this will likely cripple cross‑border online pharmacy orders that many Americans rely on for affordable medications, effectively functioning as a ban even though such imports remain technically legal. The change is framed within broader concerns about tariffs as a hidden tax on consumers, the fragility of the U.S. healthcare and prescription drug pricing system, and the political and legal leeway being exercised by the executive branch.
Scope of the New Rule
- Rule linked from the Federal Register: suspends the de minimis ($800 and under) exemption for mail shipments.
- Several commenters note it is legally dense; key elements are buried in details.
- Confusion in the thread over whether this only removes duty-free status or also tightens broader import controls.
Prescription Drug Imports
- Strong concern that this will devastate Americans who rely on cheaper medications from Canada and other countries.
- Historically, many U.S. patients used Canadian online pharmacies with U.S. prescriptions to access generics at a fraction of U.S. prices.
- One side: rule “only” removes the duty exemption; importing for personal use remains technically legal but now subject to duty, bonds, and more paperwork.
- Other side: cites a “recent change” saying packages from foreign/Canadian online pharmacies will be prohibited if the same medication is sold domestically or if the pharmacy targets U.S. buyers; expected to be enforced more strictly after Oct 22.
- Some note generics are often cheaper in the U.S. overall, but not for uninsured people and not when drugs are unavailable or in short supply domestically.
Practical and Economic Impact
- Loss of de minimis expected to:
- Add duties and administrative overhead (bonds, forms) that effectively act as a barrier for small imports.
- Raise prices and delay deliveries for art supplies, electronics (AliExpress), and other low-value goods.
- Reduce cross-border shipments, similar to EU experiences and the decline of TEMU/Shein to the U.S.
- CBP’s role: customs enforcement is explicitly its domain; some argue Congress has ceded too much oversight.
Politics and Tariffs
- Heated debate about tariffs as a tax on U.S. consumers and part of broader protectionism.
- Disagreement over legality and constitutionality of executive-driven tariff policy, including prior SCOTUS pushback.
- Timing (just before midterms) seen by some as politically risky, others doubt it will gain media traction.
Healthcare System Context & Alternatives
- Many see this as exposing how broken U.S. healthcare and drug pricing are.
- Canadian pharmacies described as “duct tape” for a failing system; removing them without a fix is seen as dangerous.
- Some mention domestic alternatives like CostPlusDrugs and discount tools (e.g., GoodRx), but doubt they fully replace lost foreign options.